Clinical Trials Logo
  1. Home
  2. Bacteremia
  3. NCT02026895

Virulence of Staphylococcus Lugdunensis in Severe Infections — VISLISI  

Bacteremia Clinical Trial

Official title:
Virulence of Staphylococcus Lugdunensis in Severe Infections

Clinical Trial Summary

The main objective is to identify new virulence factors produced by Staphylococcus lugdunensis that can be associated with clinical sign of severe infections and identified symptoms. The methodological approach is based on the comparison between the production of toxins by a given S. lugdunensis isolate classified in patients groups according to the infection clinically defined. Each group will be compared to the presence or not of studied virulence factors. Clinical features associated with toxin activity are not known for S. lugdunensis. This comparative approach is based on the hypotheses that drove to the definition of patient groups and their clinical criteria. However, in the absence of the evident correlation between production of toxins and kind of infection, the statistical evaluation will be completed by a multi-varied analysis. This approach has not been choosen first because of the multiple parameters that undergo during infection that may reveal relationships without true correlation. About the number of included patients in each defined group, if one of them does not reach the expected count, we still might extend inclusions to 3-6 months more. The presence of severe infections without usually defined risk is intriguing. For these last patients, we have planned, after their individual consent to achieve an exome sequencing. The obtained data will be compared to available resources for the human genome. By filtering data through usual protocols, we hope to able to focus onto few genes that evoke specific sensitivity to infections, e.g. severe endocarditis due to S. lugdunensis without defined risk.

Clinical Trial Description

n/a

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02026895
Study type Interventional
Source University Hospital, Strasbourg, France
Contact
Status Completed
Phase N/A
Start date December 2013
Completion date February 2016
View Details
See also
  Status Clinical Trial Phase
Completed NCT03894046 - Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex Phase 3
Active, not recruiting NCT03354338 - Amoxicillin to Prevent Bacteria and Inflammatory Biomarkers After Intensive Periodontal Therapy Phase 2
Withdrawn NCT02543957 - Factors Associated With Increased Risk of Bacteremia and Cholangitis in ERCP With Cholangioscopy
Completed NCT02210169 - RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates N/A
Completed NCT01410578 - The Value of sTREM-1, PCT, and CRP as Markers for the Detection of Sepsis and Bacteremia Among Patients With a FUO N/A
Terminated NCT00428051 - Colombia Epidemiologic Surveillance Study N/A
Completed NCT00609375 - Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen Phase 4
Terminated NCT00108433 - Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections Phase 3
Completed NCT00177736 - Pharmacodynamic Parameters of Two Different Doses of Cefepime Phase 4
Completed NCT00571259 - Prophylactic Antimicrobial Catheter Lock Phase 4
Completed NCT00027248 - Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections Phase 3
Completed NCT05585463 - Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
Recruiting NCT05950984 - Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
Completed NCT03148769 - Spanish Bacteriemia Cohort 2016: Epidemiology, Clinical Management and Prognosis Factors
Completed NCT02536352 - Effect of Supplementation of Fluoride on Maternal Periodontal Health, Preterm Delivery, and Perinatal Well-Being Early Phase 1
Completed NCT02869191 - Blood Cultures's Profitability in Intensive Care Unit
Terminated NCT01734694 - Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients Phase 4
Completed NCT01179022 - Incidence of Bacteremia Following Argon Plasma Coagulation in Patients With Endobronchial Lesions N/A
Recruiting NCT00404625 - Infections Caused by ESbL-Producing Enterobacteriaceae in Italy N/A
Completed NCT00398411 - Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells Phase 3